American Academy of Neurology (AAN), 2024

Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality

Patient Preferences for Myasthenia Gravis Treatments: A Discrete-Choice Experiment

Characteristics, Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States

Long-Term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT

Safety, Efficacy, and Patient Preference for Subcutaneous Zilucoplan in Myasthenia Gravis After Switching from Intravenous Complement 5 Component 5 Inhibitors: An Interim Analysis of a Phase 3b Study

Interactions of Fcy receptors with an IgG4 format, anti-FcRn monoclonal antibody, rozanolixizumab

Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis

Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-Label Extension Studies

Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study

The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)